Searched for: school:SOM
Department/Unit:Population Health
Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease
Sun, Pengfei; Kumar, Nitin; Tin, Adrienne; Zhao, Jing; Brown, Michael R; Lin, Zesen; Yang, Min-Lee; Zheng, Qiwen; Jia, Jia; Bielak, Lawrence F; Yu, Bing; Boerwinkle, Eric; Hunker, Kristina L; Coresh, Josef; Chen, Y Eugene; Huo, Yong; Kardia, Sharon L R; Khoriaty, Rami; Zhou, Xiang; Morrison, Alanna C; Zhang, Yan; Ganesh, Santhi K
[Figure: see text].
PMCID:8516734
PMID: 34488438
ISSN: 1524-4563
CID: 5586172
Prenatal Exposure to Nonpersistent Chemical Mixtures and Fetal Growth: A Population-Based Study
van den Dries, Michiel A; Keil, Alexander P; Tiemeier, Henning; Pronk, Anjoeka; Spaan, Suzanne; Santos, Susana; Asimakopoulos, Alexandros G; Kannan, Kurunthachalam; Gaillard, Romy; Guxens, Mònica; Trasande, Leonardo; Jaddoe, Vincent W V; Ferguson, Kelly K
BACKGROUND:Prenatal exposure to mixtures of nonpersistent chemicals is universal. Most studies examining these chemicals in association with fetal growth have been restricted to single exposure models, ignoring their potentially cumulative impact. OBJECTIVE:We aimed to assess the association between prenatal exposure to a mixture of phthalates, bisphenols, and organophosphate (OP) pesticides and fetal measures of head circumference, femur length, and weight. METHODS: RESULTS: DISCUSSION/CONCLUSIONS:Higher exposure to a mixture of phthalates, bisphenols, and OP pesticides was associated with lower EFW in the midpregnancy period. In late pregnancy, these differences were similar but less pronounced. At birth, the only associations observed appeared when comparing individuals from Q1 and Q4. This finding suggests that even low levels of exposure may be sufficient to influence growth in early pregnancy, whereas higher levels may be necessary to affect birth weight. Joint exposure to nonpersistent chemicals may adversely impact fetal growth, and because these exposures are widespread, this impact could be substantial. https://doi.org/10.1289/EHP9178.
PMCID:8612241
PMID: 34817287
ISSN: 1552-9924
CID: 5063642
A Novel COVID-19 Severity Score Is Associated with Survival in Patients Undergoing Percutaneous Dilational Tracheostomy [Meeting Abstract]
Hambrecht, A; Krowsoski, L; DiMaggio, C; Hong, C; Medina, B; McDevitt, J T; McRae, M; Mukherjee, V; Uppal, A; Bukur, M
Introduction: Tracheostomy in COVID-19 patients is a controversial and difficult clinical decision. A recent COVID-19 Severity Score (CSS) was validated to identify high-risk patients requiring hospitalization. We hypothesized that the CSS would be associated with survival in patients considered for tracheostomy.
Method(s): We reviewed 77 mechanically ventilated COVID-19 patients evaluated for percutaneous dilational tracheostomy (PDT) from March-June 2020 at a public tertiary care center. Decision for PDT was based on clinical judgment of the screening surgeons. The CSS was retrospectively calculated using mean biomarker values from admission to time of PDT consult. Primary end point was survival to discharge. The Youden index identified an optimal CSS cut point for survival.
Result(s): Mean CSS for 42 survivors vs 35 nonsurvivors was significantly different (CSS 52 vs 66; p = 0.003). The Youden index returned an optimal CSS of 55 (area under the curve 0.7; 95% CI, 43 to 72). Median CSS was 40 (interquartile range 27 to 49) in the Low CSS (<55 group) and 72 (interquartile range 66 to 93) in the high CSS (>= 55) group (Fig. 1a). Eighty-seven percent of low CSS patients underwent PDT, with 74% survival, and 61% of high CSS patients underwent PDT with only 41% surviving (Fig. 1b). Patients with high CSS had 77% lower odds of survival (odds ratio 0.2; 95% CI, 0.1 to 0.7).
Conclusion(s): Higher CSS was associated with decreased survival to discharge in patients evaluated for PDT, with a score > 55 predictive of mortality. The novel CSS can be a useful adjunct in determining which COVID-19 patients will benefit from tracheostomy. Further prospective validation of this tool is warranted. [Formula presented]
Copyright
EMBASE:2014945417
ISSN: 1879-1190
CID: 5024592
Prenatal mother-father cortisol linkage predicts infant executive functions at 24 months
Braren, Stephen H; Perry, Rosemarie E; Ribner, Andrew; Brandes-Aitken, Annie; Brito, Natalie; Blair, Clancy
The present study investigated associations between prenatal mother-father cortisol linkage and infant executive functions. Data come from an international sample (N = 358) of predominantly white and middle- to upper-class first-time parents. During late pregnancy, parents collected diurnal salivary cortisol samples and reported on levels of psychological stress. At 24 months, children completed a battery of executive function tasks. Parent cortisol linkage was operationalized as the time-dependent, within-dyad association between maternal and paternal diurnal cortisol. Results indicated that prenatal linkage was positively related to infant executive functions, suggesting that stronger mother-father cortisol linkage was associated with higher executive function scores. Additionally, this relation was moderated by paternal average cortisol levels such that executive function scores were lower when fathers had higher average cortisol levels and linkage was weak. This association suggests that elevated paternal cortisol amplifies the negative relation between lower cortisol linkage and lower infant executive function scores. Importantly, these findings were observed while controlling for observational measures of caregiving and self-report measures of psychosocial functioning and infant social-emotional behavior. These results suggest that prenatal linkage of mother's and father's stress physiology plays a potentially important part in programming and regulating infant neurocognitive development.
PMID: 34674244
ISSN: 1098-2302
CID: 5068142
Co-Occurring Dehydration and Cognitive Impairment During COVID-19 in Long-Term Care Patients [Letter]
Boockvar, Kenneth S; Mak, Wingyun; Burack, Orah R; Canter, Benjamin E; Reinhardt, Joann P; Spinner, Ruth; Farber, Jeffrey; Weerahandi, Himali
PMCID:8429357
PMID: 34599885
ISSN: 1538-9375
CID: 5037652
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1/2 mutations
Smith, Maria J; Gerber, Deanna; Olsen, Anne; Khouri, Olivia R; Wang, Yuyan; Liu, Mengling; Smith, Julia; Pothuri, Bhavana
BACKGROUND:In women with BRCA mutations, risk-reducing bilateral salpingo-oophorectomy (RRSO) has been shown to decrease gynecologic cancer-specific and overall mortality. The National Comprehensive Cancer Network (NCCN) recommends that patients with BRCA mutations undergo RRSO between the ages of 35-40 years for BRCA1 mutation carriers and between the ages of 40-45 years for BRCA2 mutation carriers, or after childbearing is complete. Currently, uptake and timing of RRSO and reasons for delays in RRSO are not well understood. OBJECTIVE:We sought to evaluate uptake and timing of RRSO among women with BRCA1/2 mutations in relation to NCCN guidelines, and reasons for delays in RRSO. STUDY DESIGN/METHODS:In this retrospective chart review, we identified women with BRCA1/2 mutations who discussed RRSO with a provider between 2012 and 2021. Uptake of RRSO was documented, and patients were classified as having timely or delay in RRSO based on NCCN guidelines. For those with delay in RRSO, reasons cited for delay were collected. Comparative statistical analyses were performed to evaluate characteristics of those with timely vs delayed RRSO. A multivariable logistic regression model was used to evaluate the associations between factors related to timing of RRSO. RESULTS:We identified 638 BRCA1/2 mutation carriers seen between 2012 and 2021. Of these patients, 306 (48.0%) had undergone RRSO and 332 (52.0%) had not. When evaluating timing of RRSO, 136 (21.3%) underwent timely RRSO, 239 (37.5%) had delay in RRSO, and 263 (41.2%) had not undergone RRSO but were younger than NCCN age guidelines so were neither timely nor delayed. Patients with delay in RRSO were significantly older at the time of genetic testing compared to those with timely RRSO (mean 49.8 vs 36.3 years; p < 0.001). Of the 306 patients who underwent RRSO, those with delayed RRSO had a significantly shorter interval between BRCA identification and RRSO compared to those with timely RRSO (median 8.7 vs 17.6 months; p < 0.001). Patients with delay in RRSO were more likely to have a personal history of cancer than those with timely RRSO (49.8% vs 37.5%; p=0.028). Of the 239 women with delay in RRSO, reasons included: 188 (78.7%) for delayed BRCA mutation identification; 29 (12.1%) for menopausal concerns; 17 (7.1%) for ongoing cancer treatment; 12 (5.0%) for coordination with breast surgery; 20 (8.4%) for miscellaneous reasons; and 19 (7.9%) with no reasons documented. In the multivariate model, older age at BRCA diagnosis (OR 0.73; 95%CI [0.68-0.78]; p<0.001) was significantly associated with delayed RRSO timing; those with BRCA2 mutation type were 7.54 times as likely to have timely RRSO compared to BRCA1 mutation carriers (OR 7.54; 95%CI [3.70-16.42]; p<0.001). CONCLUSION/CONCLUSIONS:Nearly 38% of BRCA1/2 mutation carriers undergo or have yet to undergo RRSO beyond the NCCN recommended age. The most common reason for delay in RRSO was delayed identification of BRCA mutation, noted in 79% of patients with delayed RRSO. Timely genetic testing for eligible patients can increase appropriately timed RRSO for prevention of ovarian cancer and reduction of mortality in BRCA mutation carriers.
PMID: 34171390
ISSN: 1097-6868
CID: 4925842
The impact of a Friendly Telephone Calls program on visits with physicians during pandemic [Letter]
Blachman, Nina L; Lee, Yi Shan; Arcila-Mesa, Mauricio; Ferris, Rosie; Chodosh, Joshua
PMCID:8447359
PMID: 34337742
ISSN: 1532-5415
CID: 5107692
Glucose Patterns in Very Old Adults: A Pilot Study in a Community-Based Population
Selvin, Elizabeth; Wang, Dan; Tang, Olive; Minotti, Melissa; Echouffo-Tcheugui, Justin B; Coresh, Josef
PMCID:8819510
PMID: 34191599
ISSN: 1557-8593
CID: 5586142
ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer
Kilcoyne, Aoife; Gottumukkala, Ravi V; Kang, Stella K; Akin, Esma A; Hauck, Carlin; Hindman, Nicole M; Huang, Chenchan; Khanna, Namita; Paspulati, Rajmohan; Rauch, Gaiane M; Said, Tamer; Shinagare, Atul B; Stein, Erica B; Venkatesan, Aradhana M; Maturen, Katherine E
Primary vaginal cancer is rare, comprising 1% to 2% of gynecologic malignancies and 20% of all malignancies involving the vagina. More frequently, the vagina is involved secondarily by direct invasion from malignancies originating in adjacent organs or by metastases from other pelvic or extrapelvic primary malignancies. Data on the use of imaging in vaginal cancer are sparse. Insights are derived from the study of imaging in cervical cancer and have reasonable generalizability to vaginal cancer due to similar tumor biology. Given the trend toward definitive chemoradiation for both cancers in all but early stage lesions, principles of postchemoradiation tumor response evaluation are largely analogous. Accordingly, many of the recommendations outlined here are informed by principles translated from the literature on cervical cancer. For pretreatment assessment of local tumor burden and in the case of recurrent vaginal cancer, MRI is the preferred imaging modality. PET/CT has demonstrated utility for the detection of nodal metastatic and unexpected distant metastatic disease. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
PMID: 34794599
ISSN: 1558-349x
CID: 5049542
Geographic Density and Uptake of Pre-exposure Prophylaxis (PrEP) Among Young Gay, Bisexual and Other Sexual Minority Men: A Global Positioning System (GPS) Study
Kim, Byoungjun; Chaix, Basile; Chen, Yen-Tyng; Callander, Denton; Regan, Seann D; Duncan, Dustin T
The geographic availability of pre-exposure prophylaxis (PrEP) providers is one important factor that significantly affects PrEP uptake. While most previous studies have employed spatial accessibility in static residential neighborhood definitions or self-reported healthcare accessibility, we examined the associations of the objectively measured geographic density of PrEP services with current PrEP use, using global positioning system (GPS) among sexual minority men (SMM) in New York City. 250 HIV-negative SMM participated in a 2-week GPS monitoring (January 2017-January 2018). Geographic PrEP density was measured as total numbers of PrEP providers in (1) individual activity space defined as daily path area of GPS points, (2) residential street network buffers and (3) census tract and ZIP code of residential locations. Geographic PrEP density within GPS-based activity space was positively associated with current PrEP use (prevalence ratio for 50-m activity space = 1.10, 95% confidence interval: [1.02, 1.18]). PrEP provider counts in residential buffer areas and administrative neighborhoods were not associated with PrEP use. Although it is not generalizable beyond New York City, our finding suggests the importance of daily mobility pattern in HIV prevention and PrEP implementation strategies.
PMCID:8541942
PMID: 33818642
ISSN: 1573-3254
CID: 5403712